#ISTH2022

SUPPORTED SYMPOSIA & PRESENTATION THEATERS
ISTH 2022 Supported Symposia & Presentation Theaters
(as of7/10/22)
​
The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2022 Congress in London, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis.
​
See below for session titles.
​
Live Supported Symposia and Presentation Theaters
​​
Saturday, July 9, 11:30 – 12:45 Supported Symposia
-
AAV Gene Therapies: Learnings From Clinical Trials to Inform Real World Discussions (BioMarin Pharmaceutical Inc.) ICC Capital Suites 7&12
-
Anticoagulant Advancements for VTE in All Ages and NVAF in Adult Patients (Boehringer Ingelheim) ICC Capital Suites 10&11
-
Living with ITP: Thrombotic Risk and Patient’s Perspective (GRIFOLS) ICC Capital Suite 1
-
A Key Factor: Aiming for All-Round Bleed Protection in Haemophilia A (Octapharma AG) ICC Capital Suites 14-16
-
Shining a Light on Severe Congenital Protein C Deficiency (SCPCD) (Takeda Pharmaceutical Company Limited) ICC Capital Suites 8&9
​
Sunday, July 10, 07:00 – 07:45 Supported Symposium
-
Navigating the Joint Health Journey for Patients With Hemophilia: How Can You Make A Lasting Impact? (MedScape/ISTH/Takeda Pharmaceuticals U.S.A, Inc.) ICC Capital Suite 1
​
Sunday, July 10, 12:15 – 13:00 Presentation Theaters
-
Achieving Balance with Prophylaxis in Hereditary Factor X Deficiency – Treatment Across the Ages (Bio Products Laboratory Ltd.) Presentation Theater 3
-
MRX PT DOAC – a New Way to Measure the Effect of DOACs (Nordic Biomarker) Presentation Theater 4
-
Rapid Reversal of DOACs: Current and Future Perspectives (Norgine) Presentation Theater 2
-
Managing the Challenges of IVDR Transition Together (Siemens Healthineers) Presentation Theater 1
​
Sunday, July 10, 13:15 – 14:30 Supported Symposia
-
Make the Right Call: Protecting Vulnerable Patients With Venous Thrombosis (Bayer AG) ICC Capital Suites 2-4
-
Advancing Care for Haemophilia: How Do We Keep Up With the Times? (CSL Behring) ICC Capital Suites 7&12
-
Evidence-Based Responses to Key Clinical Questions Relating to Hemophilia A Management (F. Hoffmann-La Roche Ltd) ICC Capital Suites 10&11
-
COVID-19 Coagulopathy and Long COVID: Haemostatic Changes and Implications for Diagnosis and Treatment (Haemonetics Corporation) ICC Capital Suites 17
-
Health Equity for Haemophilia Patients with Inhibitors: Can We Do More? (LFB) ICC Capital Suite 1
-
Mind the Gap: The Journey to Address Unmet Needs Across all Haemophilia Indications (Novo Nordisk) ICC Capital Suites 14-16
-
Immune Thrombocytopenia: Disease Burden and Treatment Challenges in the COVID-19 Era (Sanofi) ICC Capital Suites 8&9
​
Monday, July 11, 07:00 – 07:45 Supported Symposium
-
Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (CAT) (Anthos Therapeutics) ICC Capital Suite 17
​
Monday, July 11, 07:00 – 07:45 Presentation Theater
-
Implementing a Multimodal Approach to VTE Prevention Today (Cardinal Health) ICC Capital Suite 1
​
Monday, July 11, 12:15 – 13:00 Presentation Theaters
-
Advances in von Willebrand Disease (vWD): A View From the Clinic (CSL Behring) Presentation Theater 3
-
Driving Change: Improving Diagnosis of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls (Novo Nordisk Healthcare AG) Presentation Theater 4
-
Lupus Anticoagulant Diagnostics: Why you Need More Snakes (Technoclone) Presentation Theater 1
-
ADAMTS13 and von Willebrand Factor Axis (Werfen) Presentation Theater 2
​
Monday, July 11, 13:15 – 14:30 Supported Symposia
-
Roundtable Discussion: Clinical Challenges in Patients with Venous Thromboembolism – Following the Data (BMS/Pfizer) ICC Capital Suites 14-16
-
Improving Patient Care through Innovative Thrombosis and Haemostasis Testing. LumiraDx: Microfluidic Technology in POC Testing (LumiraDx) ICC Capital Suites 1
-
Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges (Pfizer) ICC Capital Suites 7&12
-
Improving Outcomes in Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Can We Reduce Mortality? (Sanofi) ICC Capital Suites 10&11
-
Factors to Consider: Expert Perspectives on Haemophilia A (Sobi Sanofi) ICC Capital Suites 8&9
-
A Chronic Disease Burden: Exploring the Acute and Long-term Manifestations of TTP on Patients’ Lives (Takeda Pharmaceutical Company Limited) ICC Capital Suites 2-4
Tuesday, July 12, 12:15 – 13:00 Presentation Theaters
-
Breakthrough Applications for Thrombin Generation (Diagnostica Stago) Presentation Theater 4
-
Current Advances in Deficient Factors, D-Dimer and Thrombophilia Testing (HORIBA Medical) Presentation Theater 3
-
Insights From Real World Practice to Support Haemophilia B Patients (Sobi Sanofi) Presentation Theater 1
-
Building a Future in Haemostasis: A new-age in Laboratory Workflow and Automation with the Sysmex CN-Series (Sysmex) Presentation Theater 2
​
Tuesday, July 12, 13:15 – 14:30 Supported Symposia
-
Strategies for Assessing and Managing DOAC-Related Bleeding (AstraZeneca) ICC Capital Suites 10&11
-
Focus on Females: Patient Experience & Novel Treatment Strategies in Bleeding Disorders (Octapharma AG) ICC Capital Suites 7&12
-
Advances in Diagnosis and Management of Bleeding Disorders (Roche) ICC Capital Suites 2-4
-
Medically-Ill Patients: VTE Prophylaxis in Hospital and Beyond (Sanofi) ICC Capital Suites 14-16
-
Towards Health Equity: Upcoming Standards in Haemophilia Management (Sanofi) ICC Capital Suite 1
-
Immune Thrombocytopenia: A Numbers Game? (Sobi) ICC Capital Suites 8&9
-
Looking Towards the Future: Individualizing Treatment for Patients with Congenital and Acquired Hemophilia A (Takeda Pharmaceutical Company Limited) ICC Capital Suite 17
​
For more information on these sessions, visit the online program here.